RVMD•November 17, 2026 at 7:16 PM UTCPharmaceuticals, Biotechnology & Life Sciences

RVMD Secures EU Approval for Rasonque in Pancreatic Cancer, but Valuation Still Stretched

Read source article

What happened

Revolution Medicines announced that the European Commission has approved Rasonque (daraxonrasib) for metastatic pancreatic cancer, adding an EU commercial opportunity to its strong U.S. launch. This regulatory milestone comes as the stock trades around $98, up sharply over the past year, and follows a period of intense M&A speculation that has inflated the share price. The EU nod is a necessary step toward generating revenue, but the company remains pre-revenue with an annual cash burn near $1.0–1.1 billion and key pivotal data still pending until 2026. While this approval reduces some commercial execution risk in Europe, it does not resolve the fundamental uncertainty around the durability and breadth of daraxonrasib’s efficacy or the competitive threats from other KRAS-targeted agents. The market likely anticipated this outcome, and the news may provide only a transient lift if any; the stock is already priced for significant success across multiple indications.

Implication

While EU approval expands the addressable market and validates the commercial path for daraxonrasib, it does not change the core investment thesis of potential overvaluation and crowded positioning. The company still faces significant clinical risk in the upcoming RASolute 302 and RASolve 301 trials, which will determine the drug's true potential. Moreover, the royalty monetization arrangement with Royalty Pharma encumbers future cash flows, further diluting the equity value even if the drug is commercially successful. With a negative P/E and no margin of safety, any disappointment in pivotal data or competitive setbacks could lead to sharp downside. Investors should wait for evidence of superior randomized efficacy or a material pullback to a more attractive entry point before considering new positions.

Thesis delta

The thesis shifts slightly in a positive direction operationally, as the EU approval de-risks the regulatory pathway in a major market, but this was anticipated and is largely reflected in the current price. The fundamental view remains that the stock is overvalued with limited near-term catalysts and substantial binary risk ahead. Therefore, the prior 'POTENTIAL SELL' stance is unchanged, and we would continue to trim above $115 and only reassess on a pullback or clearer pivotal data.

Confidence

High